OHDSI MEETINGS THIS WEEK
Patient-level prediction (eastern hemisphere) workgroup meeting - Wednesday at 12pm EThttps://global.gotomeeting.com/join/972917661
Population-level estimation (western hemisphere) workgroup meetings - Thursday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M3T9BZV9RSB6YNDM8WDDZMI19D-D1JL
Hadoop workgroup meeting - Friday at 11am EThttp://cloudera.webex.com/meet/sdolley
ANNOUNCEMENTS
OHDSI F2F - The deadline to register for the OHDSI F2F to take place on March 17-18th at GeorgiaTech in Atlanta is Tuesday, February 28th at 5pm . Register here:http://www.ohdsi.org/events/2017-ohdsi-collaborator-face-to-face/
OHDSI collaborator meetings - We’re looking for presenters for our weekly community meetings. If you’re interested in sharing your working with the community, please let us know by replying to this thread, or by emailing me at beaton@ohdsi.org .
COMMUNITY PUBLICATIONS
1 H-NMR with Multivariate Analysis for Automobile Lubricant Comparison.
S Kim, D Yoon, DK Lee, C Yoon and S Kim,
Journal of forensic sciences , Jul 2017
Identification of suspected automobile-related lubricants could provide valuable information in forensic cases. We examined that automobile lubricants might exhibit the chemometric characteristics to their individual usages. To compare the degree of clustering in the plots, we co-plotted general industrial oils that were highly dissimilar with automobile lubricants in additive compositions. 1 H-NMR spectroscopy was used with multivariate statistics as a tool for grouping, clustering, and identification of automobile lubricants in laboratory conditions. We analyzed automobile lubricants including automobile engine oils, automobile transmission oils, automobile gear oils, and motorcycle oils. In contrast to the general industrial oils, automobile lubricants showed relatively high tendencies of clustering to their usages. Our pilot study demonstrated that the comparison of known and questioned samples to their usages might be possible in forensic fields.
Vojtech_Huser
February 28, 2017, 5:27pm
2
There is also this recent study: (not sure if OHDSI R packages were used).
PB Ryan, MJ Schuemie, D Ramcharran and PE Stang,
Drugs & aging , 2017 03
A recently published analysis of population-based claims data from Ontario, Canada reported higher risks of acute kidney injury (AKI) and related outcomes among older adults who were new users of atypical antipsychotics (AAPs) compared with unexposed patients. In light of these findings, the objective of the current study was to further investigate the risks of AKI and related outcomes among older adults receiving AAPs.A replication of the previously published analysis was performed using the US Truven MarketScan Medicare Supplemental database (MDCR) among patients aged 65 years and older. Compared with non-users of AAPs, the study compared the risk of AKI and related outcomes with users of AAPs (quetiapine, risperidone, olanzapine, aripiprazole, or paliperidone) using a 1-to-1 propensity score matched analysis. In addition, we performed adapted analyses that: (1) included all covariates used to fit propensity score models in outcome models; and (2) required patients to have a diagnosis of schizophrenia, bipolar disorder, or major depression and a healthcare visit within 90 days prior to the index date.AKI effect estimates [as odds ratios (ORs) with 95% confidence intervals (CIs)] were significantly elevated in our MDCR replication analyses (OR 1.45, 95% CI 1.32-1.60); however, in adapted analyses, associations were not significant (OR 0.91, 95% CI 0.78-1.07)). In analyses of AKI and related outcomes, results were mostly consistent between the previously published and the MDCR replication analyses. The primary change that attenuated associations in adapted analyses was the requirement for patients to have a mental health condition and a healthcare visit prior to the index date.The MDCR analysis yielded similar results when the methodology of the previously published analysis was replicated, but, in adapted analyses, we did not find significantly higher risks of AKI and related outcomes. The contrast of results between our replication and adapted analyses may be due to the analytic approach used to compare patients (and potential confounding by indication). Further research is warranted to evaluate these associations, while also examining methods to account for differences in older adults who do and do not use these medications.